Surgical instrument with needle holder for bone anchor insertion device

USPTO granted patent US12594065B2 to BIEDERMANN TECHNOLOGIES GMBH & CO. KG for a surgical instrument connectable to a bone anchor insertion device. The instrument includes a handle portion, needle holder, actuator, and transmission member to convert rotational movement into axial needle advancement and retraction.

Radiographic imaging apparatus and control method thereof

USPTO granted Canon Kabushiki Kaisha Patent US12594049B2 for a radiographic imaging apparatus with radiation detection and communication control capabilities. The patent covers a system that stores radiographic imaging data when communication with a control apparatus is abnormal and transmits stored data once communication is restored.

Combined Notice of Filings #2 covering Electric and EG filings

FERC issued a Combined Notice of Filings listing five dockets received on April 7, 2026. The notice covers two EG (Exempt Wholesale Generator) filings and three ER (Electric Rate) filings, including dockets EG18-28, EG18-31, ER26-1726, ER26-1727, and ER26-2061. This is a routine administrative notice cataloging filings received by the Commission.

Combined Notice of Filings #1 - Multiple Electric Utility Filings

FERC issued a Combined Notice of Filings listing 33 electric utility docket filings received on April 7, 2026. The notice covers multiple rate cases (ER), electric coordination matters (EC), and long-term electric proceedings (EL) spanning various sub-dockets from 2010 through 2026. The filings are administrative in nature, documenting ongoing regulatory proceedings before the Commission.

PJM Interconnection Errata Notice Shortening Comment Period

FERC issued an errata notice shortening the comment period for PJM Interconnection, L.L.C. filing under docket ER26-1315. The notice was filed and posted on April 7, 2026, by the Secretary of the Commission. This is a routine administrative correction to the procedural schedule for the underlying proceeding.

100% tariffs on patented pharmaceuticals, key exemptions detailed

100% tariffs on patented pharmaceuticals, key exemptions detailed

Antitrust Enforcers Intensify Scrutiny of Healthcare Algorithmic Pricing

At the ABA Antitrust Spring Meeting, a panel discussed the intensifying scrutiny of algorithmic pricing tools in healthcare and data-driven industries. The Department of Justice Antitrust Division continues to file Statements of Interest emphasizing the 'starting point' theory, asserting that competitors may coordinate simply by agreeing to use the same algorithm to generate benchmark prices. California Assembly Bill 325 (AB 325), effective January 1, 2026, prohibits the use of 'common pricing algorithms' that use competitor data to stabilize prices or wages, introducing potential criminal liability for coercive conduct.

Healthcare & Life Sciences: Drug Pricing Digest - April 2026

President Trump issued a proclamation under Section 232 imposing 100% ad valorem tariffs on imported patented pharmaceuticals and associated ingredients. Companies with approved onshoring plans receive a reduced 20% rate (rising to 100% after 4 years), while those negotiating Most Favored Nation pricing agreements with HHS may qualify for exemptions. Reduced rates of 10-15% apply to products from EU, Japan, South Korea, Switzerland, Liechtenstein, and the UK under existing trade commitments.

CMS Finalizes CY 2027 Medicare Advantage and Part D Rule

Holland & Knight LLP summarizes CMS final rule for CY 2027 Medicare Advantage and Part D, effective June 1, 2026. The rule codifies Inflation Reduction Act-driven Part D redesign including out-of-pocket caps and manufacturer discount programs, while finalizing Star Ratings reforms and TPMO oversight updates. CMS also clarifies that cannabis products illegal under federal or applicable state law cannot be offered as SSBCI.

$3.2M DEA Settlement Should Caution Hospitals on Controlled-Substance Recordkeeping

The DEA reached a $3.2 million settlement with Sutter Medical Center, Sacramento and Sutter Fairfield Surgery Center to resolve 628 alleged violations of Controlled Substances Act recordkeeping and security requirements. SMCS faced 360 violations including failures to link CSOS records and notify DEA of theft/loss; SFSC faced 268 violations spanning recordkeeping, inventory, and security failures. The settlement underscores federal enforcement focus on holding healthcare providers accountable for safeguarding controlled substances against theft and diversion.